Lipophilization of somatostatin analog RC-160 improves its bioactivity and stability

Pharmaceutical Research

Volumn 16, Issue 7, 1999, Pages 1047-1053

  Dasgupta, P ^a   Singh, A T ^a,b   Mukherjee, R ^a,b  

^a NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

^b DABUR RESEARCH FOUNDATION   (India)

Author keywords

Acromegaly; GH inhibitory activity; Lipophilization; Protease resistance; RC 160; Somatostatin

Indexed keywords

GROWTH HORMONE; LONG CHAIN FATTY ACID; PEPTIDE; SOMATOSTATIN DERIVATIVE; VAPREOTIDE;

ACROMEGALY; ANIMAL CELL; ARTICLE; DRUG CONJUGATION; DRUG DESIGN; DRUG EFFECT; DRUG MECHANISM; DRUG STABILITY; DRUG SYNTHESIS; HORMONE INHIBITION; HYDROPHOBICITY; MYRISTYLATION; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY;

EID: 0032784682     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018935800052     Document Type: Article

References (28)

1. S. W. J Lamberts, W. W. de Herder, P. M. van Koesveld, J. W. Koper, A. J. van der Lely, H. A. Visser-Wisselaar, and L. J. Hofland. Somatostatin receptors: clinical implications for endocrinology and oncology. In Somatostatin and its receptors (eds. D.J. Chadwick and G. Cardew). Wiley, Chichester (Ciba Found. Symposia), pp. 222-239, 1995.
2. S. Melmed. Acromegaly, Metabolism (Suppl. 1). 45:51-52 (1996).
3. G. Gilles. Somatostatin: the neuroendocrine story. Trend. Pharmac. Sci. 18:87-95 (1997).
4. T. Reisine, D. Woulfe, K. Raynor, H. Kong, H. Heerding, J. Hines, M. Tallent, and S. Law. Interaction of somatostatin receptors with G-proteins and cellular effector systems. In Somatostatin and its receptors (eds. D. J. Chadwick and G. Cardew). Wiley, Chichester (Ciba Found. Symposia), pp. 160-170, 1995.
5. L. J. Hofland, P. M. van Koetsveld, M. Waaijers, J. Zuyderwijk, and S. W. J. Lamberts. Relative Potencies of the somatostatin analogs octreotide, BIM-23014 and RC-160 on the inhibition of hormone release by cultured human endocrine tumor cells and normal rat anterior pituitary cells. Endocrinology 134:301-306 (1994).
6. A. S. Dutta. Somatostatin. In Small Peptides: Chemistry, Biology and Clinical Studies, Elsevier, Pharmacochemistry Library, 19:293-350 (1992).
7. P. Grass, P Marbach, C. Bruns, and I. Lancranjan. Sandostatin LAR in acromegaly: Pharmakokinetic and pharmacodynamic relationships. Metabolism (Suppl. 1), 45:27-30 (1996).
8. M. R. Johnson, H. S. Chowdrey, F. Thomas, C. Grint, and S. L. Lightman. Pharmacokinetics and efficacy of he long acting somatostatin analog somutuline in acromegaly. Eur. J. Endocrinol. 130:229-234 (1995).
9. S. W. J Lamberts, A. J. van der Lely, and W. W. de Herder. Drug Therapy: Octreotide. N. Engl. J. Med. 334:246-254 (1996).
10. I. Gozes, G. Lilling, R. Glazier, A. Ticher, I. E. Ashkenazi, A. Davidson, S. Rubinraut, M. Fridkin, and D. E. Brenneman. Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptors. J. Pharmacol. Exp. Ther. 273:161-167 (1995).
11. I. Gozes, A. Bardea, A. Reshef, R. Zamostiano, S. Zhukovsky, S. Rubinraut, M. Fridkin, and D. E. Brenneman. Neuroprotective strategy for Alzheimer's disease: Intranasal administration of a fatty neuropeptide. Proc. Natl. Acad. Sci. U.S.A. 93:427-432 (1996).
12. 17) VIP Hybrid Antagonizes VIP Receptors on Non-Small cell Lung Cancer Cells. Life Sci. 61:1657-1666 (1997).
13. G. B Fields and R. L. Noble. Solid phase peptide synthesis utilizing flourenylmethoxycarbonyl amino acids. Int. J. Peptide Protein Res. 35:161-214 (1990).
14. J. P Tam, C. R. Wu, W. Liu, and J. W. Zhang. A highly selective and effective reagent for disulfide bond formation in peptide synthesis and protein folding. Proceedings of the Twelfth American Peptide Symposium. (eds. J. A. Smith and J. E. Rivier) ESCOM, Leiden, Netherlands, pp. 499-500, 1992.
15. Y. Qin, T. Ertl, K. Groot, J. Horvath, R. Z. Cai, and A. V. Schally. Somatostatin analog RC-160 inhibits growth of CFPAC-1 human pancreatic cancer cells in vitro and intracellular production of human pancreatic cancer cells in vitro and intracellular production of cyclic adenosine monophosphate. Int. J. Cancer. 60:694-700 (1995).
16. O. Singh and A. Capoor. Radioimmunoassay of gonadotropins. In A Handbook of Practical and Clinical Immunology (ed. G. P. Talwar and S. K. Gupta), CBS Publishers and Distributors, Delhi, 2:40-54, 1993.
17. M. Salahuddin. Radioiodination of Peptides. In A Handbook of Practical and Clinical Immunology (ed. G. P. Talwar and S. K. Gupta), CBS Publishers and Distributors, Delhi, 2:24-35, 1993.
18. C. A. Lipinski, F. Lombardo, B. W. Dominy and P. Feeney. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Del. Rev. 23:3-25 (1997).
19. D. Marshak. Purification of calmodulin. In Strategies For Protein Purification & characterization: A Laboratory Manual. Cold Spring Harbour Laboratory Press, pp. 93-94, 1996.
20. I. Shimon, X. Yan, J. E Taylor, M. H Taylor, M. D. Culler, and S. Melmed. Somatostatin receptor subtype-selective analogs differentially supress in vitro growth hormone and prolactin in human pituitary adenomas. J. Clin. Invest. 100:2386-2392 (1997).
21. S. Nielsen, S. Mellemkjaer, L. M. Rasmussen, T. Ledet, J. Astrup, J. Weeke, and J. O. L. Jorgensen. Gene Transcription of receptors for growth hormone releasing peptide and somatostatin in human pituitary adenomas. J. Clin. Endocrinol. Metab. 83:2997-3000 (1998).
22. Y. C. Patel and C. M. Srikant. Somatostatin Receptors. Trends Endocrinol. Metab., 8:398-405 (1997).
23. Kubota, Y. Yamada, S. Kagimoto, S. Seino, and Y. Seino. Effector coupling of somatostatin receptor subtypes on human endocrine tumors. Metabolism (Suppl. 1), 45:42-45 (1996).
24. Kaupmann, C. Bruns, F. Raulf, H. P. Weber, H. Mattes, and H. Lubbert. Two amino acids located in the transmembrane domain VI and VII determine the selectivity of pcptidc agonist SMS 201-995 for the SSTR2 somatostatin receptor. EMBO J. 14:727-735 (1995).
25. G. Liapakis, D. Fitzpatrik, C. Hoegers, J. Rivier, R. Vandlen, and T. Reisine. Identification of ligand binding determinants in the somatostatin receptor subtypes 1 and 2. J. Biol. Chem. 271:20331-20339 (1996).
26. G. Amidon, H. Lennamas, V. P. Shah, and J. R. Crison. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12:413-420 (1995).
27. W. Rubas and M. E. M. Cromwell. The effect of chemical modifications on octanol/water partition (log D) and permeabilities across Caco-2 monolayers. Adv. Drug. Del. Rev. 23:157-162 (1997).
28. R. Paradis and M. Page. New active pacitaxel amino acids derivatives with improved water solubility. Anticancer Rex. 18: 2711-2716.